Medibio
| File:Medibio Logo RGB 72DPI.jpg | |
| Publicly Traded | |
| ISIN | 🆔 |
| Industry | Medical Technology & Equipment |
| Founded 📆 | Sydney, New South Wales, Australia (1998) |
| Founder 👔 | |
| Headquarters 🏙️ | Suite 605, Level 6, 50 Clarence Street, Sydney, New South Wales , Australia |
Number of locations | 2 (2017) |
Area served 🗺️ | Global |
Key people |
|
| Members | |
Number of employees | 20 (2017) |
| 🌐 Website | medibio |
| 📇 Address | |
| 📞 telephone | |
Medibio Limited (ASX:MEB) is an Australian medical device and technology company based in Sydney, New South Wales, Australia that has developed evidence-based quantitative diagnostic test for identifying key mental health disorders. These mental health disorders include depression, anxiety, mixed depression and anxiety, panic disorder, psychosis and schizophrenia, post traumatic stress disorder PTSD, and chronic stress. Medibio's patented biomarker is based on the circadian heart rate (CHR) architecture. The company is currently conducting trials to support CE and FDA approvals.
History[edit]
Medibio was founded in 1998 as BioProspect Limited and changed its name to Medibio Limited in 2014. The company worked with Hans Stampfer and The University of Western Australia in research and development to utilize circadian heart rate (CHR) variability and proprietary algorithms to deliver a quantifiable measure in clinical diagnosis of mental health disorders.[1][2] The practical applications of this technology include mental health diagnosis analysis, monitoring and detection. Mediobio's depression diagnostics have been validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa.[3][4] In December 2014, Medibio Ltd. was officially listed on the Australian Stock Exchange.[5] Shortly thereafter, Medibio finalized their appointment of NAMSA, a United States-based medical research organization, to begin its clinical trials.[6] Medibio is collaborating with Medtronic on a wearable device and their technology to diagnose mental conditions using electrocardiogram (ECG) and circadian heart rate variability analysis utilizing a heart-monitoring patch.[7] Franklyn G. Prendergast, formerly of Mayo Clinic was appointed to the advisory board in 2015 and is working with the company.[8]
Research[edit]
Research began at The University of Western Australia with Professor Hans Stampfer's findings being published in 1998 with studies and publications still ongoing.[9] In 2015 The University of Ottawa began clinical trials to validate Medibio's technology.[10] John's Hopkins University began clinical trials with Medibio in 2015 as well.[11] In 2016 Sydney University agreed to a clinical trial with Medibio.[12] In early 2017, Mediobio and LifeQ partnered towards delivering mental wellness diagnostic and management solutions for businesses.[13]
References[edit]
- ↑ "Bioprospect Limited ASX: BPO – Farm-in Agreement with Solagran – Mr Warwick Dowse, MD". ABN Newswire. 16 January 2007. Retrieved 17 January 2017.
- ↑ "Medibio Collaborates with Emory University on PTSD Research" (PDF). Medibio Ltd. Retrieved 17 February 2017.
- ↑ Althaus, Pini (21 December 2016). "Johns Hopkins Validation Results of Medibio's (MEB.ASX) Technology". Medibio Limited. Retrieved 27 February 2017.
- ↑ "University of Ottawa Depression Study Improves Accuracy Rate to an Outstanding 86% in a Far Larger Sample" (PDF). Medibio. 2 November 2016. Retrieved 27 February 2017.
- ↑ "NOTICE GIVEN UNDER SECTION 708A (5) OF THE CORPORATIONS ACT" (PDF). Medibio Limited. 26 November 2014. Retrieved 27 February 2017.
- ↑ "Medibio Appoints US-Based CRO for its Validation Trials" (PDF). Medibio Limited. 5 December 2014. Retrieved 27 February 2017.
- ↑ Enriquez, Jof (6 January 2016). "Medtronic Announces Foray Into Wearable Tech for Mental Health". Med Device Online. Retrieved 27 February 2017.
- ↑ "Medibio Appoints Highly Distinguished US Medical Expert, Franklyn G. Prendergast, M.D., Ph.D., To Its Physician Advisory Board". Biospace. 14 April 2015. Retrieved 27 February 2017.
- ↑ Stampfer, Hans (1998). "The Relationship Between Psychiatric Illness and the Circadian Pattern of Heart Rate". Australian and New Zealand Journal of Psychiatry. Retrieved 27 February 2017.
- ↑ "Mediobio Collaborates with University of Ottawa on Research" (PDF). Medibio. 12 October 2015. Retrieved 27 February 2017.
- ↑ "Medibio's Study with John's Hopkins University of Medicine Receives IRB Approval". Biospace. 24 November 2015. Retrieved 27 February 2017.
- ↑ "Medibio Partners with Sydney University Brain Mind Centre on Clinical Study for Corporate Workplace Stress Assessment" (PDF). Medibio. 17 August 2016. Retrieved 27 February 2017.
- ↑ "LifeQ and Medibio to Deliver Scalable Mental Wellness Diagnostic and Management Tools to Empower Personal Health". Medibio. 4 January 2017. Retrieved 27 February 2017 – via BusinessWire.
External links[edit]
This article "Medibio" is from Wikipedia. The list of its authors can be seen in its historical. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
